Autologous and allogeneic high-dose therapy for melanoma

Current Oncology Reports

Volumn 3, Issue 4, 2001, Pages 338-343

  Margolin, Kim A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Advanced Melanoma; Donor Lymphocyte Infusion; Melanoma; Metastatic Melanoma; Vitiligo

Indexed keywords

TUMOR ANTIGEN;

ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; REVIEW;

ANTIGENS, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MELANOMA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035405731     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-001-0087-3     Document Type: Article

References (43)

1. Chu E, DeVita VT: Principles of cancer management: chemotherapy. In Cancer Principles and Practice of Oncology. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2001:289–306.
2. Meyers ML, Balch CM: Diagnosis and treatment of metastatic melanoma.In Cutaneous Melanoma. Edited by Balch CM, Houghton AN, Sober AJ, Soong SJ. St. Louis: Quality Medical Publishing; 1998:325–372.
3. McDermott DF, Mier JW, Lawrence DP, et al.: A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon a-2B in patients with metastatic melanoma. Clin Cancer Res 2000, 6:2201–2208.
4. Khayat D, Borel C, Tourani JM, et al.: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993, 11:2179–2180.
5. Legha SS, Ring S, Eton O, et al.: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, and dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol 1998, 16:1752–1759. This study reports the highest level of activity seen with a combination of interferon-alfa, interleukin-2, and combination chemotherapy with cisplatin, vinblastine, and dacarbazine. A remarkable result was that nearly half of the complete remission patients have remained relapse-free over 4 years. The results of this study led to a large cooperative group trial testing the contribution of the biologic response modifiers to the chemotherapy backbone.
6. Richards JM, Mehta N, Ramming K, Skosey P: Sequential chemoimmuno-therapy in the treatment of metastatic melanoma. J Clin Oncol 1992, 10:1338–1343.
7. Doroshow JH: Pharmacological basis for high-dose chemotherapy. In Hematopoietic Cell Transplantation, edn 2. Edited by Thomas ED, Blume KG, Forman SJ. Malden, MA: Blackwell Science; 1999:103–122.
8. Fields KK: Autologous bone marrow transplantation and melanoma: a focused review of the literature. Ann Plast Surg 1992, 28:70–73.
9. Sznol M: Emerging concepts in cancer vaccine development. In PPO Update 13/7, Cancer, Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1999:1–11. In this comprehensive review, Sznol concisely summarizes important aspects of tumor immunology and provides examples of the most important components of current research and the rationale for ongoing trials.
10. Shu S, Plautz GE, Krauss JC, Chang AE: Tumor immunology. JAMA 1997, 278:1972–1981.
11. Falkenburg JHF, Goselink HM, van der Harst D, et al.: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991, 174:27–33.
12. Lim SH, Coleman S: Chronic myeloid leukemia as an immunological target. Am J Hematol 1997, 54:61–67.
13. Yotnda P, Firat H, Garcia-Pons F, et al.: Cytotoxic T cell response against the chimeric p210 bcr-abl protein in patients with chronic myelogenous leukemia. J Clin Invest 1998, 101:2290–2296.
14. Falkenburg JHF, Wafelman AR, Joosten P, et al.: Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999, 94:1201–1208. One of the landmark publications demonstrating clearly that cytotoxic T cells with specific cytolytic activity against recipient CML cells and no toxicity against donor or recipient non-leukemic cells are capable of completely eradicating the leukemic relapse without any additional interventions such as chemotherapy.
15. Nabel GJ, Gordon D, Bishop DK, et al.: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A 1996, 93:15388–15393.
16. Hersh EM, Stopeck AT, Klasa R, et al.: Allovectin-7 (HLA/B2m plasmid DNA/lipid complex) therapy in metastatic malignant melanoma, phase II studies [abstract]. Proc ASCO 1997, 17:1658.
17. Overwijk WW, Lee DS, Surman DR, et al.: Vaccination with a recombinant vaccinia virus encoding a ‘self’antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4+ T lymphocytes. Proc Natl Acad Sci U S A 1999, 96:2982–2987.
18. Okamoto T, Irie RF, Fujii S, et al.: Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998, 111:1034–1039.
19. Merimsky O, Shoenfeld Y, Fishman P: The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions. Clin Rev Allergy Immunol 1998, 16:227–236.
20. Rosenberg SA: Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 1997, 18:175–182.
21. Kawakami Y, Robbins PF, Wang RF, et al.: The use of melanosomal proteins in the immunotherapy of melanoma. J Immunother 1998, 21:237–246. This review describes the important discovery of several melanomaassociated antigens that are recognized by tumor-infiltrating T cells in melanoma metastases. The characteristics of these antigens and the T cells they induce are the basis for a large proportion of current and future investigational efforts in immunotherapy for melanoma.
22. Bakker ABH, Schreurs WJ, de Boer AJ, et al.: Melanocyte lineage specific antigen gp100 is recognized by melanomaderived tumor-infiltrating lymphocytes. J Exp Med 1994, 179:1005–1011.
23. Kawakami Y, Eliyahu S, Jennings C, et al.: Recognition of multiple epitopes of the human melanoma antigen gp 100 by tumor-infiltrating T-lymphocytes associated with in vivo tumor regression. J Immunol 1995, 154:3961–3966.
24. Bakker ABH, Schreurs MWJ, Tafazzul G, et al.: Identification of a novel peptide derived from the melanocyte specific gp 100 antigen as the dominant epitope recognized by an HLAA2.1 restricted anti-melanoma CTL line. Int J Cancer 1995, 62:97–102.
25. Jimenez M, Maloy WL, Hearing VJ: Specific identification of an authentic clone for mammalian tyrosinase. J Biol Chem 1989, 264:3397–3403.
26. Chen YT, Stockert E, Tsang S, et al.: Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci U S A 1995, 92:8125–8129.
27. Porter DL, Collins RH Jr, Shpilberg O, et al.: Long-term followup of patients who achieved complete remission after donor leukocyte infusions. Biol Blood Marrow Trans 1999, 5:253–261.
28. Champlin R, Khouri I, Kornblau S, et al.: Reinventing bone marrow transplantation. Oncology 1999, 13:621–641. These authors review the clinical experience with donor lymphocyte infusions for the treatment of relapse following allogeneic transplantation and describe nonmyeloablative transplant regimens currently under investigation for benign and malignant hematologic disorders and solid tumors.
29. Huang AY, Golumbek P, Ahmadzadeh M, et al.: Bone marrowderived cells present MHC class I-restricted tumor antigens in priming of antitumor immune responses. Ciba Found Symp 1994, 187:229–240.
30. Visseren MJW, van Elsas A, van der Voort EIH, et al.: CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 1995, 154:3991–3998.
31. Bakker ABH, Marland G, de Boer AJ, et al.: Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 1995, 55:5330–5334.
32. Jäeger E, Bernhard H, Romero P, et al.: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996, 66:162–169.
33. van Elsas A, van der Burg SH, van der Minne CE, et al.: Peptidepulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLAA* 0201-binding peptides from the Melan-A/MART-1 self antigen. Eur J Immunol 1996, 26:1683–1689.
34. Marincola FM, Rivoltini L, Salgaller ML, et al.: Differential anti-MART-1/Melan A CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells. J Immunother 1996, 19:266–277.
35. Sandmeier M, Niederwieser D, Maloney DG, et al.: The effect of donor lymphocyte infusions (DLI) on chimerism and persistent disease after nonmyeloblative hematopoietic stem cell transplant (HSCT) [abstract]. Proc Am Soc Hematol 2000, 96:477a(2053).
36. Sandmeier M, Maloney DG, Hegenbart U, et al.: Nonmyeloablative conditioning for HLA-identical related allografts for hematologic malignancies. Proc Am Soc Hematol 2000, 96:479a(2061).
37. Fosså SD: Interferon in metastatic renal cell carcinoma. Semin Oncol 2000, 27:187–193.
38. Margolin KA: Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000, 27:187–193.
39. Bukowski RM: Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Semin Oncol 2000, 27:187–193.
40. Hinkel A, Tso CL, Gitlitz BJ, et al.: Immunomodulatory dendritic cells generated from nonfractionated bulk peripheral blood mononuclear cell cultures induce growth of cytotoxic T cells against renal cell carcinoma. J Immunol 2000, 23:83–93.
41. Figlin RA, Thompson JA, Bukowski RM, et al.: Multicenter, randomized, phase III trial of CD8+ tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999, 17:2521–2529.
42. Childs R, Chernoff A, Contentin N, et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablatic allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000, 343:750–758. This exciting report describes the remarkable regression of advanced metastatic renal cancer in patients whose only therapy is nonmyeloablative allogeneic stem-cell transplantation. This procedure was associated with an objective response in half of the patients and a durable response in 15% of patients. The authors observe an association between the establishment of complete donor T-cell chimerism and the achievement of an objective response that was often delayed by several months following the transplant.
43. Childs R, Bradstock KF, Gottlieb D, et al.: Non-myeloablative allogeneic stem cell transplantation as immunotherapy for metastatic melanoma: results of a pilot study [abstract]. Proc Am Soc Hematol 2000, 96:353b(5277).